omeprazole has been researched along with Liver Neoplasms in 19 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Liver Neoplasms: Tumors or cancer of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report on the clinical signs, diagnosis and 8-year course in a 54-year-old female patient with myeloma and gastrinoma with liver metastasis and associated Cushing syndrome treated for the last 3 years with the new H+/K+-ATPase inhibitor omeprazole which has successfully suppressed the massive gastric acid hypersecretion." | 8.77 | [Long-term suppression of acid secretion with omeprazole use in metastatic gastrinoma]. ( Kummer, H; Schaub, N; Schlup, M; Wegmann, W, 1988) |
| "We report on the clinical signs, diagnosis and 8-year course in a 54-year-old female patient with myeloma and gastrinoma with liver metastasis and associated Cushing syndrome treated for the last 3 years with the new H+/K+-ATPase inhibitor omeprazole which has successfully suppressed the massive gastric acid hypersecretion." | 4.77 | [Long-term suppression of acid secretion with omeprazole use in metastatic gastrinoma]. ( Kummer, H; Schaub, N; Schlup, M; Wegmann, W, 1988) |
| " Based on clearance of CYP isoform-specific substrates at the microsomal level (CLM), microsomal protein per gram of liver (MPPGL), liver weight, hepatic blood flow, hepatic clearance values (CLH) for 10 CYPs in HCC patients (n=102) were extrapolated using a predictive bottom-up pharmacokinetic model." | 1.43 | Changes in cytochrome P450s-mediated drug clearance in patients with hepatocellular carcinoma in vitro and in vivo: a bottom-up approach. ( Fang, Y; Gao, J; Gao, N; He, XP; Jia, LJ; Jin, H; Qiao, HL; Tian, X; Wen, Q; Zhang, YF; Zhou, J, 2016) |
| "Omeprazole is a drug used for treating gastro-oesophageal reflux disease and duodenal ulcers." | 1.35 | Omeprazole alleviates benzo[a]pyrene cytotoxicity by inhibition of CYP1A1 activity in human and mouse hepatoma cells. ( Kawanishi, M; Ohsako, S; Shiizaki, K; Yagi, T, 2008) |
| "Female breast cancer is one of the major causes of death among women while male breast cancer is relatively uncommon and accounts for about 1% of all breast cancers in both sexes." | 1.34 | Male breast cancer with mandibular metastasis. A case report. ( Amaddeo, P; Barbaglio, A; Faldi, F; Fontana, S; Ghilardi, R; Pericotti, S, 2007) |
| "Omeprazole is a well known activator of the aryl hydrocarbon receptor (AhR)." | 1.33 | Role of CYP3A4 in the regulation of the aryl hydrocarbon receptor by omeprazole sulphide. ( Daujat-Chavanieu, M; Fabre, JM; Gerbal-Chaloin, S; Maurel, P; Pichard-Garcia, L; Poellinger, L; Sa-Cunha, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.26) | 18.7374 |
| 1990's | 8 (42.11) | 18.2507 |
| 2000's | 6 (31.58) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Norton, JA | 1 |
| Foster, DS | 1 |
| Blumgart, LH | 1 |
| Poultsides, GA | 1 |
| Visser, BC | 1 |
| Fraker, DL | 1 |
| Alexander, HR | 1 |
| Jensen, RT | 1 |
| Chintalapati, SP | 1 |
| Patel, A | 1 |
| Conjeevaram, H | 1 |
| Gao, J | 1 |
| Zhou, J | 1 |
| He, XP | 1 |
| Zhang, YF | 1 |
| Gao, N | 1 |
| Tian, X | 1 |
| Fang, Y | 1 |
| Wen, Q | 1 |
| Jia, LJ | 1 |
| Jin, H | 1 |
| Qiao, HL | 1 |
| Shiizaki, K | 1 |
| Ohsako, S | 1 |
| Kawanishi, M | 1 |
| Yagi, T | 1 |
| Wong, H | 1 |
| Yau, T | 1 |
| Chan, P | 1 |
| Ng, IO | 1 |
| Chan, G | 1 |
| Hui, P | 1 |
| Law, WL | 1 |
| Lo, CM | 1 |
| Hedley, AJ | 1 |
| Epstein, RJ | 1 |
| Backlund, M | 1 |
| Ingelman-Sundberg, M | 1 |
| Gerbal-Chaloin, S | 1 |
| Pichard-Garcia, L | 1 |
| Fabre, JM | 1 |
| Sa-Cunha, A | 1 |
| Poellinger, L | 1 |
| Maurel, P | 1 |
| Daujat-Chavanieu, M | 1 |
| Trubetskoy, O | 1 |
| Marks, B | 1 |
| Zielinski, T | 1 |
| Yueh, MF | 1 |
| Raucy, J | 1 |
| Fontana, S | 1 |
| Ghilardi, R | 1 |
| Barbaglio, A | 1 |
| Amaddeo, P | 1 |
| Faldi, F | 1 |
| Pericotti, S | 1 |
| Yoshinari, K | 1 |
| Ueda, R | 1 |
| Kusano, K | 1 |
| Yoshimura, T | 1 |
| Nagata, K | 1 |
| Yamazoe, Y | 1 |
| Kikuchi, H | 3 |
| Hossain, A | 3 |
| Sagami, I | 1 |
| Ikawa, S | 2 |
| Watanabe, M | 2 |
| Brøsen, K | 1 |
| Gerosa, Y | 1 |
| Bernard, B | 1 |
| Lagneau, M | 1 |
| You, K | 1 |
| Hoang, C | 1 |
| Brasseur, JL | 1 |
| Opolon, P | 1 |
| Valla, D | 1 |
| Kato, H | 1 |
| Mizuno, M | 1 |
| Miyazaki, J | 1 |
| de Mestier, P | 1 |
| Graffner, H | 1 |
| Singh, G | 1 |
| Chaudry, I | 1 |
| Milsom, JW | 1 |
| Duek, SD | 1 |
| Barzilai, A | 1 |
| Schaub, N | 1 |
| Schlup, M | 1 |
| Kummer, H | 1 |
| Wegmann, W | 1 |
1 review available for omeprazole and Liver Neoplasms
| Article | Year |
|---|---|
[Long-term suppression of acid secretion with omeprazole use in metastatic gastrinoma].
Topics: Female; Gastric Juice; Gastrinoma; Humans; Liver Neoplasms; Middle Aged; Neoplasms, Multiple Primary | 1988 |
18 other studies available for omeprazole and Liver Neoplasms
| Article | Year |
|---|---|
Incidence and Prognosis of Primary Gastrinomas in the Hepatobiliary Tract.
Topics: Adult; Bile Duct Neoplasms; Disease-Free Survival; Female; Gastrinoma; Gastrins; Hepatectomy; Humans | 2018 |
Gastric and duodenal ischaemia after transarterial chemoembolisation for hepatocellular carcinoma: an unexpected but significant complication.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Duodenum; Gastrointestinal Hemorrhage; Hu | 2018 |
Changes in cytochrome P450s-mediated drug clearance in patients with hepatocellular carcinoma in vitro and in vivo: a bottom-up approach.
Topics: Algorithms; Carcinoma, Hepatocellular; Cytochrome P-450 Enzyme System; GABA Modulators; Humans; Isoe | 2016 |
Omeprazole alleviates benzo[a]pyrene cytotoxicity by inhibition of CYP1A1 activity in human and mouse hepatoma cells.
Topics: Animals; Anti-Ulcer Agents; Benzo(a)pyrene; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytochrome | 2008 |
PPI-delayed diagnosis of gastrinoma: oncologic victim of pharmacologic success.
Topics: Anti-Ulcer Agents; Appendectomy; Barrett Esophagus; Delayed Diagnosis; Gastrinoma; Gastroesophageal | 2010 |
Regulation of aryl hydrocarbon receptor signal transduction by protein tyrosine kinases.
Topics: Amino Acid Substitution; Animals; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Genistein; | 2005 |
Role of CYP3A4 in the regulation of the aryl hydrocarbon receptor by omeprazole sulphide.
Topics: Active Transport, Cell Nucleus; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Culture | 2006 |
A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Chromans; Clotrimazole; Cytochrome P-450 CYP1A2; Cytoch | 2005 |
Male breast cancer with mandibular metastasis. A case report.
Topics: Aged; Androstadienes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplast | 2007 |
Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements.
Topics: Carcinoma, Hepatocellular; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Enzyme Induction; Human | 2008 |
Different inducibility of cytochrome P-4501A1 mRNA of human and mouse by omeprazole in culture cells.
Topics: Animals; Base Sequence; Carcinoma, Hepatocellular; Cell Nucleus; Cytochrome P-450 Enzyme System; Gen | 1995 |
[Does long-term treatment with omeprazole increase the risk of cancer?].
Topics: Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Omeprazole; Risk Factors; Time Factors | 1994 |
[Cystic lymphangioma of the duodenum revealed by digestive hemorrhage and associated with exudative enteropathy].
Topics: Aged; Duodenal Neoplasms; Gastrointestinal Hemorrhage; Humans; Jejunal Neoplasms; Kidney Neoplasms; | 1993 |
Differences in inducibility of CYP1A1-mRNA by benzimidazole compounds between human and mouse cells: evidences of a human-specific signal transduction pathway for CYP1A1 induction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Carcinoma, Hepatocellular; Cell Li | 1996 |
Signal transduction-mediated CYP1A1 induction by omeprazole in human HepG2 cells.
Topics: Benzoflavones; Benzoquinones; Cytochrome P-450 CYP1A1; Enzyme Induction; Enzyme Inhibitors; Gene Exp | 1999 |
[Congress of the American College of Surgeons (ACS). San Francisco, 10-15 October 1999].
Topics: Anti-Ulcer Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cholang | 1999 |
Omeprazole-induced hypergastrinemia does not influence growth of colon carcinoma.
Topics: Adenocarcinoma; Animals; Cell Division; Colonic Neoplasms; Gastrins; Liver Neoplasms; Mice; Mice, In | 1992 |
[Treatment of Zollinger-Ellison syndrome].
Topics: Female; Histamine H2 Antagonists; Humans; Liver Neoplasms; Middle Aged; Omeprazole; Streptozocin; Va | 1991 |